Compare the efficacy, safety and compliance of oral estradiol and vaginal estriol for urogenital problems in post-menopausal women


  • Shipra Kumari Department of Obstetrics and Gynecology, S. N. Medical College, Agra, Uttar Pradesh, India
  • Monika Singh Department of Obstetrics and Gynecology, S. N. Medical College, Agra, Uttar Pradesh, India



Estradiol, Estriol cream, Post-menopausal


Background: Menopause is recognised to have occurred after 12 months of amenorrhoea for which there are no obvious pathological and physiological causes, it is retrospective diagnosis. Objective of this study was to compare the efficacy, safety and compliance of oral estradiol and vaginal estriol for urogenital problems in post-menopausal         women.

Methods: A total of 100 postmenopausal women having urogenital symptoms were selected for the prospective study. The selected patients were randomly allocated in 2 groups. Group A received 2 mg of estradiol OD for 4 weeks and then evaluated after 4 weeks. Group B received 0.5 mg of vaginal estriol cream continuously for 4 weeks at night and then evaluated after 4 weeks. Patients were followed after 1,3 and 6 months. Inclusion criteria were postmenopausal women, vaginal symptoms, urogenital symptoms. exclusion criteria were all patients having estrogen dependent neoplasia and comorbidities.

Results: For urinary complaints, symptomatic relief was assessed by AUA Score in which after 6 months; in Group A the difference in mean from baseline was 19.64±1.63 and in Group B it was 21±2.52 and was statistically insignificant from each other. For genital complaints, symptomatic relief was graded as 1, 2, 3, 4 in which grade 4 means complete relief. After 6 months of therapy 88.2% got complete relief in Group A and   91.1% in Group B. In vaginal cytological smears; in both groups, parabasal cells were reduced and superficial cells were increased after 6 months of therapy and both groups were statistically insignificant from each other. After 6 months of therapy, increase in mean value of KPI from the baseline is 24.54±10.1 in Group A and 28.6±10.11 in Group B and both groups were statistically insignificant. Endometrial thickness remained unchanged in both the groups after 6 months of therapy.

Conclusions: Both drugs were equally effective in alleviating the urogenital symptoms with no significant side effects.


Research on the Menopause in the 1990s. Report of a WHO Scientific Group. World Health Organization, WHO Technical Report Series No.866; 1996.

Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063-8.

Wilbush J. La menopause - the birth of a syndrome. Maturitas. 1979;1:145-51.

Stearns VS, Ollmer L, Lopez JF, Smith Y, Isaacs C, Hayes DF. Hot flushes. Lancet. 2002;306:1851-61.

Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population - based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351-8.

Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the hormones and urogenital therapy committee. Obstet Gynecol. 1994;83:12-8.

Manonai J, Chittacharoen A, Theppisai U. Effect of estradiol valerate and levonorgestrel on vaginal health. Eur J Obstet Gynecol Reprod Biol. 2004;115(2):190-3.

Mattsson LA, Cullberg G, Eriksson O, Knutsson F. Vaginal administration of low-dose oestradiol-effects on the endometrium and vaginal cytology. Maturitas. 1989;11(3):217-22.

Wellington K, Perry CM. Estradiol valerate/dienogest. Drugs. 2002;62(3):491-504; discussion 505-6.

Fugh-Berman A, Bythrow J. Bioidentical hormones for menopausal hormone therapy: variation on a theme. Journal of general internal medicine. 2007 Jul 1;22(7):1030-4.






Original Research Articles